Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enveric Biosciences

1.24
+0.01000.81%
Post-market: 1.250.0100+0.81%19:48 EDT
Volume:63.81K
Turnover:78.86K
Market Cap:3.06M
PE:-0.07
High:1.26
Open:1.24
Low:1.21
Close:1.23
Loading ...

Enveric Biosciences Inc: Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

THOMSON REUTERS
·
10 Jun

Enveric Biosciences Secures Notice of Allowance for Innovative Non-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Reuters
·
10 Jun

Enveric Biosciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
04 Jun

Enveric Biosciences Secures U.S. Patent for Novel Melatonin Receptor-Targeting Compounds, Boosting Sleep and CNS Therapeutics Potential

Reuters
·
03 Jun

BRIEF-Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003

Reuters
·
28 May

Enveric Biosciences announces results from EB-003 trial

TIPRANKS
·
28 May

Enveric Biosciences Announces Positive Preclinical Results for Depression Drug Candidate EB-003

Reuters
·
28 May

Enveric Biosciences Inc - Significant Improvements in Severe Chronic Depression Model

THOMSON REUTERS
·
28 May

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate Eb-003

THOMSON REUTERS
·
28 May

Enveric Biosciences Inc - Support for Safe Extended Daily Oral Administration

THOMSON REUTERS
·
28 May

Enveric Biosciences files new provisional patent application

TIPRANKS
·
20 May

Enveric Biosciences Announces New Provisional Patent Application for Promising Neuroplastogen Candidates Targeting Neurodegenerative Diseases

Reuters
·
20 May

BRIEF-Enveric Biosciences Q1 Net Income USD -2.2 Million

Reuters
·
15 May

Enveric Biosciences Q1 EPS $(1.22) Up From $(9.21) YoY

Benzinga
·
15 May

Enveric Biosciences Secures U.S. Patent for Innovative Mescaline Derivative Compounds in EVM401 Series

Reuters
·
15 May

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

THOMSON REUTERS
·
15 May

Press Release: Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Dow Jones
·
15 May

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks
·
25 Apr

Enveric Biosciences Q4 2024 GAAP EPS $(4.83) Misses $(0.23) Estimate

Benzinga
·
31 Mar

Enveric Biosciences Inc: Qtrly Loss per Share $4.83

THOMSON REUTERS
·
31 Mar